AWARDDEFINITIVE CONTRACTSmall business
Definitive contract 75N91020C00021LODESTONE BIOMEDICAL INC.
Overview
Award facts
- Net obligations
- $455K
- $455,000of $455K potential value
- Period of performance
- Sep 16, 2020 to Sep 15, 2021
- Ended
- Modifications
- 2
- Latest action Jun 11, 2021
- Contract type
- Definitive contract
- PIID 75N91020C00021
Description of requirement
SBIR PHASE I - TOPIC 405 - PROJECT TITLE: IN VIVO PHARMACOTYPING OF COMBINATION THERAPY IN PRIMARY BRAIN TUMORS FIRM FIXED PRICE - POP: 09/16/2020 - 06/15/2021
Dates and value
- Award date
- Signed on Sep 15, 2020
- Potential end of performance
- Sep 14, 2021
- Current value
- $455,000Base and exercised options
- Potential value (if all options are exercised)
- $455,000
Obligations by fiscal year of action
- FY2021: $55,000
- FY2020: $400,000
Total across 2 fiscal years: $455,000
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Jun 11, 2021. View on USAspending · Recipient on SAM.gov
Recipient
LocationLEBANON, NH
UEIKSGGUNHRF8D5
CAGE code79C36
Business sizeSmall businessSize at award, per the contracting officer
Organization typePartnership
Parent companyLODESTONE BIOMEDICAL INC.
Business types and certifications
Self-certified small disadvantaged businessFor-profit organizationLimited liability companyPartnership or LLP
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Funded by
- Department of Health and Human Services
- National Institutes Of Health
- NIH NCI
- Funded from
- National cancer institute (0849)Program activities075-0849Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Lebanon, Grafton County, New Hampshire 03766-1630
- Congressional district (place of performance)
- NH-02As reported at the time of the action
Classification and competition
Classification
Competition
- Extent competed
- Full and open competition after exclusion of sourcesD
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- Small business set aside - totalSBA
- Contract pricing
- Firm fixed priceJ
- Offers received
- 21
Solicitation and notices
- Solicitation ID
- PHS2020-1(as reported)
- Solicitation date
- Sep 23, 2019
Contract details
- Subcontracting plan
- Plan not requiredB
- Major program
- SBIR phase i: in vivo pharmacotyping of combination therapy in primary brain tumors
- Cost Accounting Standards clause
- Not applicable exempt from CASX
- Certified cost or pricing data
- Not obtained - waivedW
- Commercial procedures
- Commercial item procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Sep 15, 2020Base obligation at award: $400,000
- Latest action
- Jun 11, 2021 — Other administrative actionModification P00002; administrative: no change in scope or value
- Latest substantive action
- Feb 5, 2021 — Option exercisedModification P00001; obligation change +$55,000
- Actions by type
- Base award1
- Option exercised1
- Other administrative action1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
Socio-economic and policy
- Inherently governmental functions
- Other functionsOT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
Place and origin
- Domestic or foreign entity
- U.S. owned businessA
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7529
- Contracting office code
- 75N910
- Transactions recorded under this award key
- 3
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7529
- Funding office code
- 75N910
- Treasury accounts
- 075-2020/2020-0849-000
- 075-2021/2021-0849-000
- Object classes
- 25.1: Advisory and assistance services
- 25.2: Other services from non-Federal sources
- Disaster or emergency funding (DEFC)
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression